Global Idiopathic Pulmonary Fibrosis Market Size to Exceed USD 8.63 Billion by 2035 | CAGR of 6.43%

Global Idiopathic Pulmonary Fibrosis Market Size to Exceed USD 8.63 Billion by 2035

According to a Research Report Published by Decisions Advisors & Consulting, The Global Idiopathic Pulmonary Fibrosis Market Size is expected to Grow from USD 4.35 Billion in 2024 to USD 8.63 Billion by 2035, at a CAGR of 6.43% during the forecast period 2025-2035.  

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Idiopathic Pulmonary Fibrosis Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Nintedanib, Pirfenidone, and Others), By Mode of Action (Antifibrotic Agents, Tyrosine Kinase Inhibitors, and Others), By End-User (Hospitals and Clinics, Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035."    

Get Detailed Report Description Here: https://www.decisionsadvisors.com/reports/idiopathic-pulmonary-fibrosis-market               

The market for diagnosing, treating, and managing idiopathic pulmonary fibrosis (IPF), a chronic lung illness marked by progressive lung tissue scarring with unexplained origins, is a specialist area of the worldwide healthcare business. Further, changing lifestyle choices, such as increased smoking rates and exposure to environmental pollutants, create a market for therapies for idiopathic pulmonary fibrosis. In addition to workplace exposure to hazardous materials like asbestos and chemical compounds, risky behaviours, including smoking tobacco and recreational drug use, are contributing to the rising prevalence of idiopathic pulmonary fibrosis (IPF). Moreover, increased investment, improved illness detection, regulatory incentives for the development of orphan drugs, and improvements in antifibrotic therapy are some of the factors propelling market expansion. However, patient access and market penetration are restricted by the current antifibrotics' high drug costs, few therapy alternatives, delayed diagnosis, and unfavourable side effects.

The nintedanib segment accounted for the largest share in 2024 and is projected to grow at a substantial CAGR over the forecast period.       

Based on the drug type, the idiopathic pulmonary fibrosis market is divided into nintedanib, pirfenidone, and others. Among these, the nintedanib segment accounted for the largest share in 2024 and is projected to grow at a substantial CAGR over the forecast period. Globally, the drug is used extensively to treat the sickness. Additionally, nintedanib aids in stabilising lung function until the transplant procedure is finished. Nintedanib is currently approved for the treatment of idiopathic pulmonary fibrosis in over 70 countries.

The antifibrotic agents segment accounted for a significant share in 2024 and is anticipated to grow at a rapid pace over the forecast period.     

Based on the mode of action, the idiopathic pulmonary fibrosis market is segmented into antifibrotic agents, tyrosine kinase inhibitors, and others. Among these, the antifibrotic agents segment accounted for a significant share in 2024 and is anticipated to grow at a rapid pace over the forecast period. These drugs lessen lung function degradation and lower the risk of abrupt respiratory deterioration associated with high morbidity and mortality. The antifibrotic medication is currently being used in clinical settings to prevent the rate of loss in forced vital capacity (FVC) in patients with progressive lung fibrosis.

The hospitals and clinics segment dominated the market in 2024 and is anticipated to grow at a significant CAGR during the forecast period.     

Based on the end user, the idiopathic pulmonary fibrosis market is divided into hospitals and clinics, pharmacies, and others. Among these, the hospitals and clinics segment dominated the market in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Hospitals are increasingly using multidisciplinary teams to manage complex situations and ensure patients receive comprehensive care. Additionally, hospital pharmacists are more qualified to manage and deliver medications for innovative treatments, such as antifibrotic medications, which often call for careful monitoring and adjustment.

Asia Pacific is expected to hold the majority share of the global idiopathic pulmonary fibrosis market during the forecast period.       

Asia Pacific is expected to hold the majority share of the global idiopathic pulmonary fibrosis market during the forecast period. The management of idiopathic pulmonary fibrosis, which has become well-established at a quick pace due to rising ailment prevalence, improved access to healthcare facilities, and an increasing focus on early detection, is the main driver of the Asia Pacific region's dominant position. Australia will be confronted with stiff competition from China, Japan, India, and South Korea, particularly Japan, which is leading the way in lung transplant programs and the development of cutting-edge drugs.

North America is anticipated to grow at the fastest pace in the global idiopathic pulmonary fibrosis market during the forecast period. North America presents a high-value opportunity for the management of idiopathic pulmonary fibrosis (IPF) because of the region's multiple top pharmaceutical and biotechnology businesses, substantial R&D programs, and improved healthcare infrastructure. In the region, the United States and Canada have the highest awareness of the illness and cutting-edge treatments like anti-fibrotic drugs and lung transplant programs with government healthcare funding.

Major vendors in the global idiopathic pulmonary fibrosis market are Boehringer Ingelheim International GmbH, United Therapeutics Corporation, Cipla Inc., Bristol-Myers Squibb Company, Hoffmann-La Roche Ltd, FibroGen Inc., Galapagos NV, Jubilant Pharma Limited (Jubliant Cadista Limited), MediciNova Inc., Merck & Co. Inc., Horizon Therapeutics Public Limited Company. Biogen, Avalyn Pharma Inc., Promedior, Inc., Horizon Therapeutics, CSL Behring, Kadmon Corporation LLC, and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development   

• In December 2025, GRI Bio reported that their Phase 2a trial of GRI-0621 in patients with idiopathic pulmonary fibrosis (IPF) achieved important objectives, demonstrating that the medication was well tolerated, enhanced lung function (FVC), and showed biomarker alterations indicating lung regeneration and fibrosis resolution.

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the idiopathic pulmonary fibrosis market based on the below-mentioned segments:  

Global Idiopathic Pulmonary Fibrosis Market, By Drug Type

• Nintedanib
• Pirfenidone
• Other

Global Idiopathic Pulmonary Fibrosis Market, By Mode of Action

• Antifibrotic Agents
• Tyrosine Kinase Inhibitors
• Other

Global Idiopathic Pulmonary Fibrosis Market, By End User

• Hospitals and Clinics
• Pharmacies
• Other

 Global Idiopathic Pulmonary Fibrosis Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa